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Chapter I: Introduction 
 
 
In a cohort study of 224 maintenance hemodialysis (MHD) patients, Noori, et al. found 
that both a higher dietary intake of phosphorus (P) and a ratio of higher P to protein (pro) 
intake were associated with increased mortality risk in hemodialysis (HD) patients.(1)  
Furthermore, dietary P restriction to control serum P is usually tied to a reduction in pro 
intake, which is associated with muscle wasting and poor survival.(2)  One highly prevalent 
complication of end stage renal disease is protein energy wasting (PEW), a state of 
decreased body protein stores and fat mass, which is strongly associated with increased 
morbidity and mortality in the hemodialysis (HD) population.(3)  The purpose of this study 
was to analyze the extent to which diet composition is associated with PEW parameters 
(serum chemistry, body mass, muscle mass, and dietary intakes).   
It was hypothesized that the patients whose diets contained the lowest P/pro ratio would 
demonstrate the fewest clinical indicators of PEW.  Results from this and future studies 
may help in designing diets to minimize PEW in the HD population. 
As part of an initial screening phase for a collaborate multi-centered interventional clinical 
trial involving HD patients from both Michigan (United States) and Selangor (Malaysia), 
data was collected from several HD clinics in Klang Valley, an area in Malaysia centered 
in Kuala Lumpur.  The diverse ethnic population is this area, comprised of Indian, Malay, 
and Chinese patients, differs vastly from the predominately African American patient pool 
found in Michigan.  To the best of our knowledge, this is the first study to assess the 
relationship between the ratio of P/pro intakes and measures of PEW in a group of 
Malaysian MHD patients.   
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CHAPTER II: REVIEW OF LITERATURE 
 
Chronic kidney disease and end-stage renal disease 
According to the United States Renal Data System (USRDS), a surveillance system that 
collects, analyzes, and reports information about chronic kidney disease and end-stage 
renal disease (ESRD) in the United States, there were 661,648 prevalent cases of ESRD 
in the U.S. in 2013, an increase of 68% since 2000. (4)  The Malaysian Society of 
Nephrology also maintains a registry of dialysis patients, reporting annually on ESRD 
trends.  Malaysia has experienced a similar rise in the number of prevalent dialysis patients, 
with a 63% increase from 2005 to 2014. (5)  Long-term survival on dialysis remains poor, 
with a 54% survival rate after five years of ESRD onset in Malaysia and after three years 
in the United States. (6; 7)  Cardiovascular disease (CVD) comorbidity, reported at ten to 
thirty times higher in CKD patients as compared to the general population, partially 
explains increased mortality rates observed with CKD.  In Malaysia, CVD related 
comorbidity accounted for 37% of all deaths for ESRD patients in 2014. (7) This 
interrelationship of CKD and CVD metabolic derangements is referred to as cardiorenal 
(CRS) syndrome.  The underlying pathophysiologies in CRS include a myriad of hormonal, 
hemodynamic, and CKD related factors, such as inflammation, calcium-phosphate 
imbalance, and anemia.(8) 
 
In both the United States and Malaysia, diabetes is the principal cause of CKD, followed 
by hypertension. Types of renal replacement therapy (RRT) that replace the non-endocrine 
functions of the kidney include dialysis (both hemodialysis and peritoneal) hemofiltration, 
and hemodialfiltration. While a kidney transplant, regarded as the gold standard in RRT, 
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does restore regulatory hormones, abnormalities of bone and mineral metabolism persist 
in most patients. (9) 
 
Protein Energy Wasting 
The term protein energy wasting (PEW), characterized by a loss of body pro mass and fuel 
reserves, was proposed by the International Society of Renal Nutrition and Metabolism 
(ISRNM) in 2007. Etiologies of PEW include multiple factors that affect nutrient 
metabolism, as outlined in Table 1.    
Table 1 
 
Causes of PEW 
Decreased Nutrient Intake 
Anorexia 
Dietary Restrictions 
Depression 
Obstacles to food 
purchases/preparation 
Decreased physical activity 
Endocrine/Hormonal Dysfunction 
Insulin Resistance 
Decreased insulin-like growth 
factor-1 
Vitamin D deficiency 
Hyperparathyroidism 
Increased pro catabolism 
Decreased anabolism 
Inflammation 
Oxidative and carbonyl stress 
Metabolic acidosis 
Volume overload 
Comorbidities  
Diabetes 
CVD 
Congestive heart failure 
Nutrient losses during dialysis 
(3) 
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The pathophysiology of PEW is complex and involves overlapping mechanisms as 
depicted in Figure 1 (3; 10; 11) Estimated prevalence of PEW ranges from twenty to fifty 
percent, with higher rates observed during the later stages of CKD due to activation of pro-
inflammatory cytokines, hypercatabolic states and declines in nutrient intakes.(12) 
Figure 1 
 
Schematic representation of the causes and manifestations of the pro–energy 
wasting syndrome in kidney disease 
 
 
 
Reprinted from reference (11) 
 
 
 
PEW has been associated with higher morbidity and mortality and poorer quality of life 
(QOL) in ESRD patients.  (13)  Four clinical indicators proposed by the ISRNM for the 
diagnosis of PEW in CKD are outlined in Table 2.  PEW is evident if criteria for at least 
three of the four categories [serum chemistry, body mass index (BMI), muscle mass, and 
dietary intake] are met.(3)   
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Table 2 
Criteria for the clinical diagnosis of pro-energy wasting in chronic kidney disease 
Serum Chemistry  
 
Serum albumin <3.8 g/dla 
Serum prealbumin (transthyretin) <30 mg/dl (for 
maintenance dialysis patients only)a  
Serum cholesterol <100 mg/dla 
BMI BMI (edema-free) <23b 
Unintentional weight loss over time: 5% over 3 months 
or 10% over 6 months 
Total body fat percentage <10% 
Muscle Mass Reduced muscle mass 5% over 3 months or 10% over 6 
months 
Reduced mid-arm muscle circumference areac (reduction 
>10% in relation to 50th percentile of reference 
population) Creatinine appearanced 
Dietary Intake Unintentional low dietary pro intake <0.80 g/kg/day for 
at least 2 months for dialysis patients or <0.6g/kg/day for 
patients with CKD stages G2–5 
Unintentional low dietary energy intake <25 kcal/kg/day 
for at least 2 months 
 
aNot valid if low concentrations are due to abnormally great urinary or gastrointestinal pro losses, liver 
disease, or cholesterol-lowering medicines 
bA lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for 
example, post-dialysis dry weight. 
cMeasurement must be performed by a trained anthropometrist 
dCreatinine appearance is influenced by both muscle mass and meat intake 
dCan be assessed by dietary diaries and interviews, or for pro intake by calculation of normalized pro 
equivalent of total nitrogen appearance (nPNA or nPCR) as determined by urea kinetic measurements.
(11)
 
 
 
 
PEW Criteria   
1. Serum chemistry 
Albumin  
Hypoalbuminemia is a strong predictor of both cardiovascular and all-cause mortality in 
all stages of CKD.   In the Nutritional and Inflammatory Evaluation in Dialysis Study, an 
observational analysis of over 3000 maintenance HD patients, both a low normalized 
protein nitrogen appearance (nPNA), a surrogate for dietary pro intake, and an 
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inflammatory state were associated with low serum albumin.(14; 15)  It was noted that nPNA, 
a measurement of net pro degradation calculated using several dialysis parameters, might 
overestimate dietary pro intake due to catabolism of endogenous nitrogen in states of 
inflammation. (16) Albumin, a negative acute phase reactant, has been criticized as a reliable 
marker of malnutrition. Albumin is a water-soluble negatively charged pro synthesized in 
the liver.  Functions include maintaining oncotic pressure, modulating coagulation by 
preventing platelet aggregation, binding free radicals and bacterial toxins and heavy metals, 
and transporting molecules such as fatty acids, thyroid hormones, steroids, bilirubin, 
calcium, and magnesium in plasma. (17) Serum levels of albumin fall due to fluid overload, 
infection, and inflammation, which trigger mechanisms leading to increased degradation 
and reduced production. Many dialysis clinics use albumin level as a qualitative rationale 
for supplement use, placing unsupported importance on this marker as an indicator of 
malnutrition.  Albumin may preferably be utilized as a marker underlying illness and 
inflammation.(18; 19; 20) 
 
Serum Cholesterol 
Hypercholesterolemia in the general population is a known cardiovascular risk factor; 
however, within the HD population an inverse association of total cholesterol with 
mortality is observed.  Dyslipidemia in CKD, which may be indicated by elevated plasma 
cholesterol, hypertriglyceridemia, high lipoprotein(a) [Lp(a)], low high-density lipoprotein 
cholesterol (HDL-C) or dysfunctional HDL particles is highly prevalent in ESRD patients.  
Elevated low-density lipoprotein cholesterol (LDL-C), and thus total cholesterol, is not a 
distinct characteristic of uremic dyslipidemia.  Reduction in LDL-C in patients not taking 
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lipid-lowering medication may be the result of inflammation and malnutrition.  
Furthermore, although serum LDL-C may not be elevated, this lipoprotein is often 
modified by oxidation and carbamylation with an increase in the proportion of small dense 
LDL (sdLDL) subtype. (21; 22; 23) 
 
2. Body Mass Index (BMI) 
Whereas normal weight BMI within a healthy population is associated with a lower all-
cause mortality risk, a higher BMI improves survival in both CHD, heart failure and 
dialysis patients.(24; 25)  This phenomenon is known as the “obesity paradox” or “reverse 
epidemiology.”  (15; 26)  However, this survival advantage for cardiovascular mortality 
within the HD population is lost in the presence of inflammation, as indicated by both CRP 
and albumin levels.(27)  It is speculated that a higher lean body mass, not fat mass, is 
responsible for the protective effects observed within the higher BMI groups.(25) 
 
3. Muscle Mass 
Anthropometric measures of skeletal muscle mass are an indirect assessment of muscle 
protein. Since about sixty percent of total body protein is located in skeletal muscle, muscle 
wasting may indicate a loss of muscle protein in response to poor nutritional intake.  
Anthropometric measurements used to estimate muscle mass include triceps skinfold 
thickness (TSF), an estimation of body fat, mid-upper arm circumference (MAC), and 
mid-arm muscle area (MAMA) or mid-arm muscle circumference (MAMC), a formula 
which indirectly estimates muscle mass (see Table 3). TSF is a measurement taken using 
calipers at the mid-line on the posterior surface of the arm over the triceps muscle. MAMC 
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is a calculated measurement derived from deducting TSF from mid-upper arm 
circumference. An arm muscle area equation that corrects for bone area can provide a more 
accurate assessment of bone-free muscle area; however, the corrected equation is neither 
validated for elderly patients, nor appropriate for use in obese individuals. (28)  Using the 
non-fistula arm, three measurements of TSF and MAC are typically taken after dialysis, 
and either the average or highest value is used for comparison to standard percentiles of a 
reference population (e.g. NHANES I).  Efforts have been made to develop standardized 
MAMC tables specific to the hemodialysis population.  A higher MAMC, an indicator of 
lean body mass, and higher TSF, an indicator of fat mass, have each been associated with 
a decrease in mortality in hemodialysis patients. (29; 30) 
Table 3 (31) 
Mid arm fat area (AFA) AFA (cm2) = 
𝑀𝐴𝐶 (𝑐𝑚)𝑥 𝑇𝑆𝐹(𝑐𝑚)
 2
 – 
𝜋 𝑥 (𝑇𝑆𝐹)2
4
 
Mid arm muscle circumference area (MAMA) MAMA (cm2) = 
[𝑀𝐴𝐶 (𝑐𝑚)−(𝜋 𝑥 𝑇𝑆𝐹)]2
4𝜋
 
Mid-arm muscle Circumference (MAMC) MAMC (cm) = MAC (cm) – 
[𝜋 𝑥 𝑇𝑆𝐹 (𝑐𝑚)] 
Body frame size is determined by a person's wrist circumference in relation to his height 
(https://www.nlm.nih.gov/medlineplus/ency/imagepages/17182.htm) 
Values less than the 5th percentile for both arm muscle area and arm fat area indicate severe depletion.  Values 
between the 5th and 10th percentiles for both arm muscle area and arm fat area represent moderate depletion 
 
Several studies have demonstrated successful use of a dynamometer to measure handgrip 
strength as an indirect assessment of muscle mass in the HD population.  A recent study of 
330 HD patients found that both muscle strength and muscle mass were strong predictors 
of mortality, with HGS demonstrating a stronger association with mortality when 
compared to muscle mass. (32) With similar results found in measurements of HGS taken 
both before and after HD sessions, this functional test is emerging as a reliable indicator of 
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muscle mass, although current research is still lacking sufficient data to establish 
parameters to define muscle wasting.  (33; 34; 35) 
Body composition measurements, such as bioimpedance analysis (BIA), are frequently 
used to evaluate fluid balance in the HD population.  These devices can also measure 
several nutritional related markers, such as lean and fat tissue mass (23).  Given the HD 
population is prone to fluid shifts between intra and extracellular spaces, anthropometric 
and body composition devices that cannot distinguish between different body 
compartments of tissue, fat mass and fluid may inaccurately estimate LBM.  (36; 37) BIA 
estimates total body water (TBW) and lean and fat tissue masses by measuring resistance 
(or impedance) to the flow of an electrical current passed through the body.  Hydration 
status, blood pressure, age and gender can alter the bioelectrical impedance, providing 
misleading results.(38)  Recently, ultrasound techniques that account for fluid shifts are 
emerging as a useful tool for estimating LBM.(39) 
 
4. Dietary Intake 
Unintentional inadequate pro and energy intake is causally linked to PEW.  Declines in 
appetite occur in the early stages of CKD and may be exacerbated by multiple causes such 
as uremic metabolites and imposed dietary restrictions. (2; 12) As CKD progresses, appetite 
and intake continue to decline as the dialysis treatment itself can result in physiological 
and metabolic effects which impact appetite and missed meals during treatment.(40) 
 
Nutritional Assessment Tools 
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As part of the nutrition care process, assessment of the HD patient includes both a medical 
history (nutrition intake, biochemical data, medical tests and procedures, anamnesis) and a 
physical examination (anthropometric measurements, signs of fat and muscle wasting) to 
determine diagnosis, intervention, monitoring and evaluation. (41; 42)  A 2012 survey of 599 
Registered Dietitians, 91% of whom worked in the US, revealed that collection of dietary 
intake is not a standard clinical practice due to time and resource constraints.  70% of 
dietitians collect intake data only if abnormal laboratory results are found.  Two-thirds of 
dietitians reported analyzing nutrient intake based on estimations without software use.(43)  
Blood chemistry, such as albumin, serum P, potassium, Kt/V (a measurement of treatment 
adequacy where K = dialyzer clearance of urea, t = dialysis time, and V = volume of 
distribution of urea, approximately equal to patient's total body water), lipoproteins, 
electrolytes, glucose, and nPCR (normalized pro catabolic rate), also known as normalized 
pro nitrogen appearance (nPNA) provide valuable information of physiological imbalances 
and nutritional deficiencies. (44)  Use of nPNA, which measures net protein degradation, is 
considered a valid reflection of dietary protein intake (DPI) in steady state conditions.  PNA 
may overestimate DPI during periods of inflammation, be inaccurate for obese, 
malnourished and edematous patients, and typically underestimates dietary pro intake by 
approximately 6–8 g of pro per day. (14; 16)  
Nutrition focused physical examinations, conducted to detect nutritional deficiencies and 
complete anthropometric and body composition measurements, though gaining popularity 
in clinical practice, are still used primarily in research.  Several screening tools and scoring 
systems, such as the subjective global assessment (SGA) and the Geriatric Nutritional Risk 
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Index (GNRI), and are available to evaluate and monitor changes to nutritional status of 
the HD patient.(45) 
 
 
 
Phosphorus Homeostasis 
Phosphorus, the second most abundant mineral in the body, is found in every cell.  In an 
adult, about 85% is complexed with calcium as hydroxyapatite in the bone and 15% is 
distributed in the intracellular space throughout fluids and soft tissues, with less than 1% 
found in the plasma.   P is not only a structural component of phospholipids (the major 
component of cell membranes), nucleotides and nucleic acids, but is also involved in 
several metabolic processes (e.g. is a buffering agent in maintaining pH, stored chemical 
energy in the form of adenosine tri-phosphate (ATP), and cell signaling through 
phosphorylation and dephosphorylation).(46) 
 
Physiological process of regulating net phosphate balance 
Intestinal Absorption of Phosphate 
Ingested P is absorbed both passively and actively through the duodenum, jejunum and 
ileum of the gastrointestinal tract (GIT) (47).  The primary route of P absorption in the GIT 
is via passive paracellular diffusion, linearly associated with luminal phosphate 
concentration, so that a higher dietary intake of P results in increased total amount of 
absorption.  P is also actively transported via sodium-phosphate 2b (NaPi-2b) co-
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transporters across the enterocyte. (48; 49)  Additionally, calcitriol, or 1,25(OH)2D, stimulates 
intestinal phosphate absorption by enhancing expression of NaPi-2b co-transporters. (50) 
 
Phosphorus Distribution in the body  
Following absorption, inorganic phosphate in the extracellular fluid moves freely in and 
out of the skeleton, along with calcium, as a consequence of bone remodeling. This critical 
inorganic phosphate component in the extracellular space makes up less than 0.1 percent 
of total body P at a concentration of approximately 1 mmol/liter (3.1 mg/dl).(46; 49) 
 
Renal Reabsorption of Phosphorus 
In a healthy kidney, approximately 75% of filtered P is reabsorbed by the glomerulus in 
the proximal tubule across the hormonally regulated type 2 sodium phosphate co-
transporters, NaPi-2a and NaPi-2c. (51; 52) The distal tubule, loop of Henle and collecting 
duct reclaim the remaining P.  The kidneys excrete excess P in the amount of approximately 
700-900 mg per day.(49)  With diminished functioning of the nephrons in CKD, the kidney 
lose their ability to excrete excess phosphorus, resulting in hyperphosphatemia.  
 
Hormonal Regulatory Mechanisms of Serum Phosphorus  
In order to understand the underlying pathways involved in P homeostasis and the difficulty 
in managing hyperphosphatemia in CKD, a brief review of the hormonal mechanisms of P 
homeostasis is provided.  As depicted in Figure 2, the interplay between fibroblast growth 
factor-23 (FGF-23), parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D3 
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(Calcitriol or 1,25(OH)2D) results in a negative feedback loop which regulates P 
homeostasis.   
 
 
 
Figure 2 
Reprinted from reference(50) 
 
Fibroblast growth factor-23 (FGF-23) 
FGF-23, a hormone synthesized in the osteoclasts, regulates P balance by promoting P 
excretion and inhibiting vitamin D circulation.  A high dietary intake of P stimulates the 
secretion of FGF-23, which in turn down regulates the expression of the NaPi co-
transporters, resulting in phosphaturia.  An increase in FGF-23 also limits intestinal P 
absorption by reducing vitamin D production.  FGF-23 inhibits renal 25-hydroxyvitamin 
D 1- hydroxylase, the enzyme responsible for the conversion of 25(OH) D to 1,25(OH)2D 
and also stimulates 24-hydroxlase production, a catabolic pathway for 1,25(OH)2D. As 
nephron capacity diminishes, FGF-23 will rise in a physiological response to maintain 
serum P levels.  Not until the later stages of CKD are elevated serum P levels observed.  
(53; 54) 
PTH, 1,25(OH)2D and FGF23 reciprocally regulate their own 
synthesis and control serum phosphate. In contrast, serum phosphate 
or phosphate load can regulate production of PTH, 1,25(OH)2D and 
FGF23. Solid lines indicate stimulation of production or increase in 
serum level. Broken lines mean inhibition of production or decrease 
in serum level.  PTH and 1,25(OH)2D are also regulated by serum 
calcium (not shown in the figure).  
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Parathyroid hormone (PTH) 
Although the primary role of PTH is to regulate serum calcium levels, it has a secondary 
effect in maintaining P homeostasis.  By down regulating NaPi-2a and NaPi-2c in the 
proximal renal tubule brush border, PTH reduces reabsorption of phosphate in the kidneys. 
(55) An elevated PTH also increases FGF-23 production, leading to diminished intestinal 
phosphate absorption and increased renal phosphate excretion.  Through a conflicting 
effect, PTH indirectly enhances intestinal phosphate absorption by increasing the activity 
of 1-α-hydroxylase enzymes, thus stimulating renal 1,25 D synthesis and also stimulates 
release of calcium and phosphate from the bone. (56; 57)   
 
 
1,25-dihydroxyvitamin D3 (Calcitriol or 1,25(OH)2D) 
Vitamin D inhibits phosphate excretion directly repressing PTH and increases intestinal P 
absorption by up-regulating NaPi-2b expression; however, unlike calcium, vitamin D is 
not essential for the absorption of P.(58; 59) 
To summarize, an elevation in PTH and FGF23 promote phosphaturia by down-regulating 
sodium-P co-transporters in renal proximal tubule cells.  FGF-23 also limits dietary P 
absorption by reducing 1,25-dihydroxyvitamin D concentrations. 
 
Hyperphosphatemia in Chronic Kidney Disease 
Hyperphosphatemia, defined as high serum P levels greater than 1.46 mmol/L,  
is common in late stage CKD and is associated with coronary artery calcification (CAC), 
the development of secondary hyperparathyroidism (SHPT), left ventricular hypertrophy 
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(LVH), mineral bone disorders (MBD), all-cause and cardiovascular mortality.(60)  
Atherosclerotic and medial artery calcifications are two types of CAC.  Whereas 
calcification of the intima, or innermost layer of the vasculature, is associated with 
atherosclerosis resulting from inflammatory mediators and elevated lipids, medial artery 
calcification is associated with stiffening of the blood vessels associated with age, diabetes, 
and CKD.   Phosphate can stimulate the calcification of vascular smooth muscle cells 
(VSMCs), which comprise the majority of medial cells.  This osteochondrogenic 
transformation occurs independently of PTH and calcitriol levels.(61; 62)  Phosphate has both 
indirect and direct effects on PTH secretion and the development of secondary 
hyperparathyroidism in CKD.  High dietary P (via increased circulating concentrations of 
FGF-23) lowers calcitriol levels, thus stimulating PTH. (61)  Chronic hyperphosphatemia in 
CKD leads to hyperplasia of the parathyroid glands, resulting in elevated PTH levels (63)  
This increase in PTH stimulates release of P from the bone, leading to CAC.  Both dietary 
phosphate and PTH increase FGF-23 levels.  Consequences of prolonged exposure to FGF-
23 in CKD include increased prevalence LVH, resulting from direct inducement of 
cardiomyocyte hypertrophy via the phospholipase C (PLC) γ/calcineurin/nuclear factor of 
activated T-cells (NFAT) pathway. This cardiovascular complication affects 
approximately 75% of patients beginning RRT. (64) 
 
Sudden death, arrhythmia, and unknown were the most common causes of cardiac death 
reported in the USRDS and Hemodialysis (HEMO) study.   LVH, cardiac fibrosis, and 
electrolyte anomalies may have been the underlying factor in these CVD deaths. (21) 
Numerous studies have found an association between elevated serum P and an increased 
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risk in cardiovascular morbidity and mortality in ESRD patients, which may be attributed 
to the presence of CAC and accelerated atherosclerosis. (65)   
 
Phosphate levels are central to chronic kidney disease-mineral and bone disorder (CKD-
MBD), a syndrome that defines the mineral, hormonal, bone remodeling anomalies, and 
vascular and soft tissue calcification that occur in CKD.  Abnormalities in calcium, P, FGF 
23, PTH, and vitamin D metabolism lead to CKD-MBD and are associated with increased 
morbidity and mortality. (66) 
 
Phosphate control in dialysis 
Removal of phosphate during the dialysis procedure differs from urea or other small 
molecules.  Water molecules bind to P, converting what was originally a small molecule 
into one of medium size, making passage through dialysis pores more difficult.  Transfer 
rate of phosphate from intra to extracellular compartments additionally limits removal 
during dialysis.  Slow shifts from the intracellular, or inaccessible space, to the extracellular 
compartment and accessible plasma pose a barrier to phosphate removal.  As a result, 
serum P levels drop quickly during the first hour of dialysis, and then stabilize; therefore, 
longer dialysis sessions result in greater P removal.   With dietary P intakes of 0.8 to 2.0 
grams per day, the average P removal of 800–1200 mg/session does not remove enough P. 
Use of phosphate binders is commonplace as an adjunct therapy to both dietary restriction 
and P removal from dialysis; however, these complementary measures of P control should 
not downplay the importance of dietary P restriction.  Within a healthy population, a high 
dietary P intake, even in the absence of elevated serum P, is associated with increased 
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mortality.(67)   A drop in serum P levels as a result of reduced dietary P intake and P binders 
use has been shown.(60; 68; 69)  However, relying on measures of serum P to gauge dietary 
control of this mineral has been criticized as unreliable due to inaccurate measurement 
techniques, frequency and timing of serum samples, and tendency with daily fluctuations 
in serum levels, potentially providing false assurance that P intake is controlled.  
Alternative biomarkers, such as FGF-23 and PTH have been suggested as better measures 
of cumulative P burden. (70; 71)  
 
Metabolic Acidosis 
Metabolic acidosis is a CKD induced complication as a result of reduced hydrogen ion 
excretion, primarily from the metabolism of sulfur containing amino acids.  Although 
buffers, such as bicarbonate, are added to the dialysate to correct the acidosis, many 
patients remain acidotic. Metabolic acidosis stimulates net pro catabolism, increases 
oxidation of branched chain amino acids (BCAA), suppresses albumin synthesis, 
negatively impacts bone metabolism, and impairs glucose tolerance. (72) Correction of 
acidosis may reduce pro wasting and restore BCAA muscle pro concentration; however, 
treatment of acidosis may only improve impaired pro synthesis in the absence of 
inflammation. (73; 74) 
 
Diets that produce large acid loads from the consumption of excess nucleic and amino acids 
in meats coupled with inadequate intakes of organic bases from fruits and vegetables may 
not only lead to low normal plasma bicarbonate concentrations, but also may impair 
calcium and pro metabolism. (75) 
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Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) 
CKD-MBD, a term originating from the Kidney Disease Improving Global Outcomes 
(KDIGO) group, describes the complex of mineral and skeletal disorders and vascular and 
soft tissue calcification resulting from abnormalities of calcium, P, PTH, or vitamin D 
metabolism caused by CKD.  Mineral bone disorders are among the non-traditional risk 
factors which contribute to the high rate of cardiovascular morbidity and mortality 
observed in CKD.  (76)  Efforts to control one factor can negatively impact remaining 
factors.   For example, vitamin D supplements, often prescribed to HD patients, can 
increase the risk of hyperphosphatemia through increased GIT absorption of phosphate as 
well as stimulation of bone resorption. (77; 78; 79) 
 
Dietary Phosphate 
Challenges in menu planning and dietary adherence exist for the HD population as they are 
instructed to restrict dietary P while increasing protein to 1.2 grams per kg body weight, 
with an emphasis of at least 50% of protein coming from foods of high biological value 
(animal based foods).(31)  Instruction presented to patients with hyperphosphatemia in 
limiting dietary P, usually provided as a list of high P foods to avoid, may have the 
unintended consequence of a reduced protein intake.  Currently, HD patients are counseled 
to reduce intake of dietary P by limiting or restricting foods high in P, including meat, 
poultry, fish, dairy, beans, lentils, and nuts.  This educational practice may explain why 
improved survival among HD patients with prescribed dietary P restriction has not been 
found.(80)  Additional dietary restrictions for sodium, potassium and fluid make meal 
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planning and dietary adherence burdensome.  Dietary protein intake for most dialysis 
patients reported at < 1.0 gram per kg/day is inadequate to preserve muscle.   A diminished 
pro intake as a result of limiting dietary P may lead to PEW.  Both low dietary pro intakes, 
elevated dietary P intakes and elevated ratios of dietary P/pro intakes have been associated 
with increased mortality in MHD patients.(1; 81)  Ideally, HD patients would benefit from a 
diet which is both high in pro and low in bioavailable P.   Using a ratio of milligrams of P 
per gram of pro, or P/pro ratio, to identify foods which are both high in pro and low in P 
has been suggested as a potential strategy in meal planning.  Taking into account loss of P 
through various cooking methods, P bioavailability, and pro to P ratios, D’Alessandro, et. 
al has proposed a phosphorus pyramid tool (see Figure 3) as a guide to choosing foods 
both high in protein and low in bioavailable P.  Authors of the pyramid suggested an upper 
limit of 12 mg/g to identify foods with a favorable phosphorus to protein ratio(82), a level 
in agreement with The National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI) guidelines of a recommended a daily P intake of 10 to 12 mg/g 
of protein.(83)  Animal proteins vary in their phosphorus and protein content.  A whole egg 
contains 6 g of protein and 86 mg of phosphorus, whereas the egg white contains 3.6 g 
protein and only 5 mg of phosphorus, a P/pro ration of less than 2 mg/gram.(84)   
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Figure 3  
Phosphorus Pyramid
   
reprinted from reference(82) 
 
About 40 to 60% of organic P, found in animal based foods and plants, is absorbed, whereas 
the bioavailability of inorganic P, found in processed foods, is almost 100%.  Given 
humans do not express the enzyme phytase, which is required to hydrolyze phytic acid or 
phytate, the storage form of P found in plants, the P content of plant pro may not reflect 
actual absorption.(84)  Yet, this diminished bioavailability of phosphorus from vegetarian 
sources of protein is not considered in renal menu planning, nor reflected in nutrient data 
bases. 
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Phosphorus additives, used by the food industry as acidity regulators, preservatives, 
thickeners, emulsifiers, flavor enhancers and stabilizers, may contribute as much as 1000 
mg/d of phosphorus to the diet.(85; 86)  A recent 2010 survey of almost 2400 processed 
grocery items revealed that 44% contained added P.(87)  Currently, the United States 
Department of Agriculture (USDA) food composition data base lists total amount of P per 
serving, but does not distinguish between inorganic and organic P content.  Additionally, 
the P content listed in nutrient databases does not always reflect the actual P content, and 
has been shown to underestimate P by as much as two to three fold. (88)  Both the USDA 
and the Ministry of Health in Malaysia require that manufacturers label for the presence of 
phosphates or polyphosphates on food labels; however, P amount is not a requirement for 
the nutrient fact panel.  Because the amount of P is not listed as a nutrient on food labels, 
HD patients must be educated in identifying inorganic P additives, such as “monosodium 
phosphate”, “phosphoric acid”, and “sodium hexametaphosphate”, on ingredients labels.  
Despite food labeling laws, an independent analysis of food labels of enhanced 
uncooked meat and poultry products found that manufacturers do not always 
disclose additives ingredients, making it impossible to estimate phosphorus and 
potassium content.(89)   Fast foods, processed meats such as ham and sausage, processed 
cheeses, canned fish, baked goods and cola type beverages, typically contain large amounts 
of added phosphate.(90)   
Additionally, various cooking methods have been evaluated to measure their effect on P 
content.  Boiling sliced meats in soft water or use of a pressure cooker has been shown to 
reduce P content as much as fifty percent while preserving pro content.(91)  Phosphorus 
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content of pasta, rice, fresh and frozen vegetables can be reduced from 7% up to 43% by 
soaking and boiling methods.(92)  
 
Phosphate Binders 
In conjunction with limiting dietary P, both prescription and non-prescription phosphate 
binders are taken with meals to reduce P absorption in the gastrointestinal tract.  Binders 
are generally classified as calcium based and non-calcium based, with the most commonly 
prescribed binders reported as calcium-based agents despite known associations with 
cardiovascular calcification.  Calcium based binders, such as calcium carbonate and 
calcium acetate, are inexpensive, tolerated well, and can lower parathyroid levels, factors 
most likely related to their continued widespread use.  In patients with elevated serum 
calcium levels, known CAC or low serum PTH levels, calcium based binders are 
contraindicated.  Two non-calcium based binders, sevelamer and lanthanum, are both 
associated with increased gastrointestinal side effects and sevelamer binds with bile salts, 
reducing lipid levels and potentially interfering with the absorption of fat soluble vitamins.  
Among all chronic disease categories, the HD population has one of the highest pill 
burdens.  Results from a cross-sectional study of 233 prevalent US dialysis patients found 
that from an average burden of eleven pills, 49% were phosphate binders with a 70% 
patient adherence rate.(93; 94) 
 
P absorption in the intestine is dependent upon the amount dietary P, bioavailability, use 
of P binders, and presence of 1,25(OH)2 vitamin D.  Additional barriers to controlling P 
may be related to patient education.  Erroneous beliefs that phosphate restriction is not 
23 
 
 
 
necessary with binder use, poor adherence to binder use, unknown associations between 
hyperphosphatemia and CAC, and confusion in which foods are high in P may all be 
associated with  hyperphosphatemia.(95) 
 
The dialysis diet contradicts a healthy eating pattern.  Difficulty in planning and 
implementing dietary restrictions often results in inadequate nutrient intakes.  Whole 
grains, pulses, nuts, fruits and vegetables are typically restricted in the renal diet due to 
their higher content of potassium and P, yet intake of these foods are associated with 
reduced CVD and overall mortality.(96; 97; 98) 
Dietary P intake can be reduced without compromising pro consumption by choosing foods 
with P/pro ratios less than 12 mg/g, avoiding foods with phosphate additives, and 
employing cooking techniques which lower the P content.(82; 99) 
Poor outcomes related to both hyperphosphatemia and PEW within the HD population 
have been well documented; however, to our knowledge, there have been no published 
studies examining intakes of P/pro ratios and PEW relationships in Malaysian HD patients.    
 
CHAPTER III: Methodology 
 
Study Design and Patient Recruitment 
This cross sectional study was part of a baseline screening protocol for an interventional 
Vitamin E tocotrienol clinical trial entitled PATCH (Palm Tocotrienols in Chronic 
Hemodialysis) to evaluate treatment effects on lipoprotein panels and inflammatory 
biomarkers.  Patients were recruited from two dialysis non-governmental organization, or 
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NGO, (National Kidney Foundation) clinics and two government hospitals in the Klang 
Valley, Malaysia, between October 2015 through March 2016. 
A sample of sixty MHD patients taken from four clinics (15 patients per clinic) were chosen 
from a larger screening pool (40 patients per clinic) based on the completion of data 
recorded. 
Inclusion criteria for the study included patients aged 18-70 years, willing to provide 
informed consent, receiving thrice weekly HD treatment for at least three months.  
Exclusion criteria included poor adherence to prescribed medication and HD regimen and 
impaired cognitive and functional abilities.   This study (Nutritional Status and Lifestyle 
Assessment among HD Patients in Malaysia) was approved by the Medical Research and 
Ethics Committee, Ministry of Health, Malaysia (NMRR-15-865-25260) and Medical 
Research Ethics Committee of National University of Malaysia (NN-039-2015). 
 
Demographic and medication data collection 
 
Demographic and prescription medication information obtained from the medical chart 
was reviewed with the patient for accuracy.   
 
Anthropometric and body composition measurements  
 
Pre and post dialysis weights were taken using a SECA digital scale (Model 220, SECA, 
Germany) and height was measured using a stadiometer to derive BMI (kg/m2).  Triceps 
skinfold thickness (TSF) measurement was taken on the non-fistula arm using a Harpenden 
skinfold caliper (HSK-BI, British Indicators, West Sussex, UK). Mid-upper arm 
circumference (MAC) was measured using a non-stretch Lufkin® metal measuring tape 
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(Apex Tool Group, LLC, NC, USA).  International Society for the Advancement of 
Kinanthropometry (ISAK) techniques were employed in the measurements for MAC and 
TSF(100).   MAMC and MAMA measurements were derived using the formulas listed in 
Table 3.  Hand grip strength (HGS) was measured using a Jamar dynamometer (BK-7498; 
Fred Sammons, Inc., Burr Ridge, IL) on the non-fistula hand prior to the patient’s dialysis 
session.  Three measurements were taken in the standing position, and the mean value was 
used in all statistical analyses.  All anthropometric measurements were performed by an 
International Society for the Advancement of Kinanthropometry (ISAK) trained dietitian 
to eliminate inter-observer variation.  Prior to the HD session, body composition 
measurements were completed using a portable bio-impedance spectroscopy monitor 
(Body Composition Monitor, Fresenius Medical Care, Bad Homburg, Germany).  The 
body composition monitor (BCM) used body weight, height, and measurements of whole 
body intracellular water (ICW) and extracellular water (ECW) using bioimpedance 
spectroscopy to determine lean tissue mass (LTM), adipose tissue mass (ATM) and 
overhydration (OH).(101) 
 
Biochemical analysis  
 
Serum samples for routine renal biochemistry (serum albumin, potassium, P, hsCRP, and 
lipid profiles) were analyzed using standard automated laboratory techniques by an 
external laboratory (Roche/Hitachi 912 System, Roche Diagnostics, Tokyo, Japan). 
 
 
3-day dietary recall collection and analysis 
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Per KDOQI guidelines, 3-day dietary recalls, including two non-dialysis and one dialysis 
day, were collected by trained dietitians using household measures to estimate portion 
sizes.(102)  Nutrient analysis of the diet records were analyzed using the Nutritionist Pro 
software (Nutritionist Pro™ 2.2.16, First DataBank Inc., 2004).  Dietary energy intake 
(DEI) and dietary pro intakes (DPI) were calculated based on the patient’s dry weight. 
 
QOL (Quality of Life) 
 
The Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney disease-specific 
measure of health-related quality of life (HRQOL), was administered by a trained dietitian. 
The survey contains questions related to generic chronic disease as well 24 kidney disease 
specific questions.  A scoring instrument was used to summarize the questions into four 
scores: effects of kidney disease, burden of kidney disease, SF-12 physical composite, and 
SF-12 mental composite [SF-12 refers to the generic core derived from the Medical 
Outcomes Study Short Form 36 (MOS SF-36), which measures eight domains: physical 
functioning, role limitations due to physical health, role limitations due to emotional 
problems, energy/fatigue, emotional well-being, social functioning, pain and general 
health].  Scores ranged from 0%, equivalent to maximum disability, to 100%, equivalent 
to zero disability.(103)   
 
 
PEW assessment 
 
Patients satisfying PEW criteria per the ISRMN were identified, and PEW prevalence was 
assessed.  Serum chemistry, BMI, muscle mass, and dietary intake parameters used 
included albumin < 3.8 mg/dL, BMI < 23 kg/m2, MAMC below the 10th percentile of the 
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normal population from the NHANES I study, and a dietary energy intake of < 25 kcals/kg 
body weight, respectively.(31; 104)   
 
Statistical analysis 
 
Variables are presented as mean ± SD, or frequency (percentages).  The normal distribution 
for continuous variables was assessed using Kolmogorov-Smirnov (K-S) test.   
Comparisons were performed by the Student’s-t and Mann-Whitney tests for continuous 
variables, with and without normal distribution, respectively.  Comparisons of frequencies 
were carried out by the Fisher test.  Differences between groups were analyzed using one-
way ANOVA and Kruskal-Wallis H Tests, with and without normal distribution, 
respectively.  Linear relationships for continuous variables were evaluated using Pearson’s 
correlation.  Categorical variables were evaluated for association using Pearson’s Chi-
Square test.  Statistical analyses were carried out using SPSS version 23 (IBM, Chicago, 
IL, USA).  Statistical significance was set at P < 0.05 for all evaluated parameters.   A non-
significant p value of 0.05 < p ≤ 0.10 was used for discussion purposes.
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CHAPTER IV: RESULTS 
 
Patient Characteristics  
Table 4 outlines the demographics of the sample (n=60) HD population.  Almost half of 
the patient population was Chinese, over one-third Malay, and over one-eighth Indian.  
Males and females were equally distributed among the sample population.  Over two-thirds 
of the group had at least a secondary education and over two-thirds were unemployed.  
 
Table 4 Demographic characteristics of the study population 
 
Demographics (n=60)  
Age (years) 55.1 ± 13.3 
Ethnicity (%)  
    Chinese 29 (48.3%) 
    Malay 21 (35%) 
    Indian 9 (15%) 
    Others 1 (1.7%) 
Sex   
    Males (%) 32 (53.3%) 
    Females (%) 28 (46.7%) 
Marital Status (%)  
    Married 48 (80%) 
    Single  12 (20%) 
Education  
    None 4 (6.7%) 
    Primary 15 (25%) 
    Secondary 28 (46.7%) 
    College/University 13 (21.7%) 
Employed  
    Yes 17 (28.3%) 
    No 43 (71.7%) 
Data are expressed as mean ± SD or percentage 
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Anthropometric and body composition measurements were compared between genders as 
outlined in Table 5.  As anticipated, both mean and highest HGS measurements, lean tissue 
mass, height, and MAC was found to be significantly higher for males when compared to 
females. 
 
 
Table 5 Anthropometric and Body Composition Measurements   
 
 ALL 
(n=60) 
Men 
 (n= 32) 
Women 
(n=28) 
P for 
comparison 
between 
genders 
Age (y) 55.1 ± 13.3 55.4 ± 14.5 54.8 ±12.0 0.609 
Time on dialysis (mo) 90.9 ± 70.8 98.1 ± 73.9 82.9 ± 67.5 0.366 
Body weight (kg) 62.9 ± 18.8 64.8 ± 23.3 60.7 ± 11.7 0.534 
Stature (cm) 156.7 ± 7.8 160.8 ± 6.6 152.0 ± 6.2 <0.0005 
BMI (kg/m2) 25.4 ± 6.3 24.8 ± 7.3 26.1 ± 5.0 0.103 
MAC (cm) 30.1 ± 6.3 29.0 ± 6.7 31.3 ± 5.7 0.017 
TSF(mm) 18.7 ± 8.9 15.0 ± 6.1 23.0 ± 9.7 0.001 
MAMC (cm) 24.2 ± 5.1 24.3 ± 5.4 24.1 ± 4.8 0.801 
MAMA (cm2) 48.0 ± 22.1 48.5 ± 26.2 47.5 ± 16.7 0.722 
Lean Tissue mass (kg) 32.8 ± 10.9 38.1 ± 11.9 26.8 ± 5.0 <0.0005 
Fat Tissue Mass (kg) 21.7 ± 10.4 19.4 ± 11.5 24.4 ± 8.4 0.002 
HGS – mean (kg) 18.6 ± 6.1 21.7 ± 6.4 15.1 ± 3.2 <0.0005 
HGS – highest (kg) 19.8 ± 6.3 22.9 ± 6.7 16.4 ± 3.3 <0.0005 
 
BMI: body mass index; MAC: mid-arm circumference; TSF: triceps skin fold; MAMC: mid-arm muscle 
circumference; MAMA: mid-arm muscle area; HGS: hand grip strength 
Data are expressed as mean ± SD; Mann-Whitney U Test  
Statistically significant variables are given in bold 
 
 
Average intakes from the three-day diet recall for HD nutrients of concern were evaluated 
against KDOQI guidelines and between genders as demonstrated on Table 6.  As expected, 
overall intake for males was higher than that for females.  Intakes for P, sodium, and fluid 
fell within KDOQI guidelines; however, neither males nor females met calorie goals of 30 
to 35 kcals per kg or pro goals of 1.2 grams per kg body weight.(31) 
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Table 6 Nutrient Intake Analysis of 3 Day Diet Recall 
 
Nutrient Intake Analysis 
 All  Men 
 (n= 32) 
Women 
(n=28) 
P for 
comparison 
between 
genders 
NKF 
KDOQI 
guidelines(31) 
Energy 
(kcals) 
1445 ± 393 1512 ± 454 1370 ± 299 0.163 Based on 
BW 
Pro (g) 54 ± 18 57 ± 19 50 ± 18 0.197 Based on 
BW 
Potassium 
(mg) 
990 ± 403 1049 ±449 923 ± 340 0.229 Based on 
serum levels 
Sodium 
(mg) 
2511 ± 
1583 
2419 ± 
1226 
2060 ± 910 0.219 <2400 mg 
P (mg) 618 ± 214 667 ± 227 563 ± 189 0.062 10-17 
mg/kg/day 
(~630-1071) 
Fluid (ml) 1002 ± 325 1064 ± 331 932 ± 309 0.118 750-1500 
cc/day 
DEI 
(kcals/kg 
dry wt.) 
24.0 ± 7.7 24.4 ± 7.8 23.6 ± 7.8 0.709 30-35 
kcals/kg 
DPI (gms 
pro/kg dry 
wt) 
0.90 ± 0.38 0.9 ± 0.35 0.9 ± 0.41 0.704 1.2 gms/kg 
aBWef^ 
 
^edema-free adjusted body weight 
Data are expressed as mean ± SD as analyzed by Student’s t-test 
 
 
P/pro Ratio 
 
Average ratio of P/pro intake for the entire sample population was 11.9 mg/g ± 3.2.  P/pro 
ratio was further stratified into favorable (< 12 mg/g) and unfavorable (> 12 mg/g) groups 
of P/Phos intakes (see Table 7)(82).  Average ratios of P/pro intake of the favorable and 
unfavorable group were 9.8 ± 1.6 and 15 ± 2.3, respectively.  Differences in various 
biochemical, anthropometric and dietary intakes between the favorable and unfavorable 
groups were analyzed.   P/pro ratio, serum potassium, dietary P, dietary pro, and KDQOL 
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SF-12 physical composite scores were significantly improved with favorable P/pro intakes 
when compared to unfavorable intakes.  Favorable P/pro intakes were also associated with 
higher intakes of protein per kg of body weight, lower total serum cholesterol and reduced 
inflammation, as measured by hsCRP. 
Table 7 Relationship of P/pro ratio (<12 mg/gram and >12 mg/gram) and 
biochemical, anthropometric and dietary intake 
 
 P/pro ratio <12 
mg/gram 
(n=35)  
P/pro ratio 
 > 12 mg/gram 
(n=25) 
P value 
P/pro ratio 
(mg/gram) 
9.8 ± 1.6 15 ± 2.3 <0.0005 
Serum Phos 
(mg/dL) 
5.36 ± 1.3 5.39 ± 1.7 0.921 
Serum K 
(mEq/L) 
2.81 ± 1.0 
(n=10) 
3.5 ± 0.39 
(n=12) 
0.019 
Serum alb 
(g/dL) 
3.96 ± 0.36 3.84 ± 0.34 0.204 
Total 
cholesterol 
(mg/dL) 
162 ± 32 179 ± 48 0.100 
Lean tissue 
mass 
33.5 ± 11.5 32.3 ± 10.2 0.762 
Fat tissue mass 22.0 ± 11.6 21.3 ± 8.7 0.781 
ECFv/TBW 1.97 ± 0.45 1.78 ± 0.34 0.111 
BMI (kg/m2) 25.8 ± 7.2 25.9 ± 4.9 0.601 
hsCRP (mg/L) 5.00 ± 4.9 7.6 ± 7.5 0.105 
Dietary Phos 
(mg) 
559 ± 190 702 ± 223 0.013 
Dietary Pro (g) 59 ±19 47 ± 15 0.033 
DPI (grams/kg) 0.97 ± 0.4 0.80 ± 0.3 0.086 
DEI (kcals/kg) 24.1 ± 7.6 24.0 ± 8.3 0.956 
KDQOL SF-12 
Physical 
Composite 
46 ± 9 40 ± 8 0.010 
MAMC (cm) 25.1 ± 5.5 23.0 ± 4.2 0.112 
MAMA (cm2) 51.8 ± 26.3 42.6 ± 13.2 0.114 
Mean HGS (kg) 19.2 ± 6.5 17.7 ± 5.5 0.361 
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Phos: P; K: Potassium; alb: albumin; ECF: extra cellular fluid: TBW: total body water; hsCRP: high 
sensitivity C-reactive pro; DPI: dietary pro intake; DEI: dietary energy intake; KDQOL: Kidney Disease 
Quality of Life 
Data are presented as mean ± SD; statistical significance measured by Kruskal-Wallis H Test 
Statistically significant variables are given in bold 
 
 
As illustrated in Figure 4, favorable P/pro intakes were associated with a lower serum 
potassium (K), hsCRP, improved KDQOL SF-12 physical composite scores, higher HGS, 
and MAMC.  The favorable ratio is influenced equally by P and pro intakes. 
 
Figure 4 Relationship of P/pro Ratios and various clinical indicators 
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The mean hsCRP in the favorable and unfavorable P/pro groups were 5.0 ± 4.9 and 7.6 ± 
7.5 (p = 0.105), respectively, as depicted in Figure 5.  Although not significant, these 
differences reflect a trend towards increased inflammation with higher P/pro ratio intakes.   
 
Figure 5 Relationship of P/Pro Ratio  
(< 12 mg/gram and > 12 mg/gram) and hsCRP 
 
 
 
Within each ethnic group, 76% of Chinese and 57% of Malay patients had P/pro intakes in 
the favorable range (< 12 mg/g) in comparison to 11% of Indian patients, as illustrated in 
Figure 6. 
 
 
0
5
10
15
20
25
30
35
0.0 5.0 10.0 15.0 20.0 25.0
H
S
C
R
P
 (
M
G
/L
)
P/PRO RATIO 
Phos/Pro < 12 mg/g and hsCRP Phos/Pro > 12mg/gram and hsCRP
34 
 
 
 
Figure 6 Comparison of P/pro Ratios and Ethnicity 
 
 
Pearson’s Chi-Square (p value = 0.004) 
 
 
 
 
 
 
In comparing diet and exercise habits between favorable and unfavorable P/pro intakes, 
those patients consuming unfavorable ratios were 44% less likely to exercise in comparison 
to those consuming favorable ratios, who were 65% more likely to exercise.  Both groups 
reported similar dietary habits regarding food preparation, food consumption outside of the 
home, and dietary counseling (see Figure 7). 
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Figure 7  
 
Comparison of P/pro ratios and diet/exercise habits 
 
 
 
 
Fisher’s Exact Test Chi-Square   
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Phosphate Binders  
Among the phosphate binders prescribed to this Malaysian population, 91.7% take calcium 
carbonate, with less than 12% using non-calcium based binders as depicted in Figure 8. 
 
 
Figure 8 Prescribed Phosphate binders  
 
Frequency Pie Chart 
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Measures of Muscle Mass 
As illustrated in Table 8, in comparing various measures of muscle mass, MAMC and 
MAMA were significantly correlated with measurements of lean tissue mass, fat tissue 
mass and BMI.  Mean HGS was significantly correlated with MAMA, and lean tissue mass. 
 
 
Table 8 Matrix of Pearson’s correlation coefficients among HGS, anthropometric, 
and body composition variables 
 
 
Variable BMI MAMC MAMA Lean 
Tissue 
mass 
Fat 
tissue 
mass 
BMI (kg/m2)      
MAMC (cm) 0.752**     
MAMA (cm2) 0.815** 0.962**    
Lean tissue 
mass 
0.448** 0.447** 0.517**   
Fat tissue 
mass 
0.878** 0.637** 0.710** 0.123  
Mean HGS 
(kg) 
0.167 0.238 0.255* 0.645** 0.014 
P < 0.01**  n= 60 (32 men and 28 women) 
P < 0.05* 
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Anthropometric, body composition and biochemical measurements of those HD patients 
who answered “yes” when asked if they engaged in any form of exercise were compared 
to those patents who reported no physical activity (see Table 9).   Those who exercised 
had a significantly lower BMI (22.3 ± 3.8) than non-exercisers (26.7 ± 6.7).  Exercisers 
also had a significantly lower fat tissue mass (16.8 ± 5.6) and MAMC (21.7 ± 5.3) than 
non-exercisers (23.8 ±11.3, 25.3 ± 4.7, respectively).  Although not significant, those who 
reported exercising showed trends towards higher serum HDL, serum albumin and lower 
hsCRP levels.  
 
Table 9 Anthropometric, Body Composition and Biochemical Measurements of 
exercisers vs non-exercisers  
 
 
Do you 
exercise? 
Yes (n=18) No (n= 42) P value 
BMI (kg/m2) 22.3 ± 3.8 26.7 ± 6.7 0.012 
Mean HGS (kg) 19 ± 6.4 18 ± 6.1 0.741 
Serum HDL 
(mg/dL) 
43 ± 14 41 ± 11 0.528 
Serum hsCRP 
(mg/L) 
4.6 ± 5.4 6.7 ± 6.4 
 
0.216 
Serum alb 
(mg/dL) 
4.0 ± 2.4 3.9 ± 3.9 0.219 
Lean tissue 
mass 
32.5 ± 8.9 32.9 ± 11.7 0.880 
Fat tissue mass 16.8 ± 5.6 23.8 ±11.3 0.017 
MAMC (cm) 21.7 ± 5.3 25.3 ± 4.7 0.011 
Data are expressed as mean ± SD as analyzed by one-way ANOVA 
Statistically significant variables are given in bold 
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PEW 
The following diagnostic criteria was used to identify patients with a PEW diagnosis: 
 
 Alb < 3.8 mg/dL 
 BMI < 23 (kg/m2) 
 MAMC < 10% (percentile of the normal population from the NHANES I 
study)(31) 
 DEI < 25 kcals/kg 
 
 
As depicted in Figure 9, among those patients with three diagnostic criteria for PEW a 
higher percentage (20%) consumed unfavorable P/pro intakes compared to 11% 
consuming favorable intakes.  Conversely, 20% of those patients with no PEW parameters 
were in the favorable P/pro group in contrast to 8% in the unfavorable group.  While not 
significant, a larger sample size may reveal greater differences in P/pro intakes among the 
PEW and non- PEW groups. 
 
Figure 9 Relationship of PEW and P/pro Ratio  
 
 
Pearson’s Chi-Square; p = 0.515 
8%
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Table 10 outlines PEW prevalence for both the entire population and within each ethnicity.  
Overall PEW prevalence in this population was calculated at 15%.  In comparison to 
Chinese and Indian ethnicities, Malay patients exhibited the fewest clinical indicators of 
PEW, while 22% of Indian patients and 17% of Chinese patients had three diagnostic PEW 
criteria in comparison to 9% of Malay patients.  
Table 10  
 
Prevalence of PEW 
 
Overall PEW Prevalence:  
No diagnostic PEW criteria 
  
15% 
One diagnostic PEW criteria 
  
48% 
Two diagnostic PEW criteria 
  
22% 
Three diagnostic PEW criteria  15% 
 
 
PEW prevalence within Ethnicities 
Ethnicity 
 
Number of PEW parameters (% within ethnicity) P value 
None One Two Three 0.110 
Malay 29%  29%  33%  9%  
Chinese 10%  59%  14%  17%  
Indian 0%  67% 11%  22%  
Others 0%  0%  100%  0%  
Fisher’s Exact Test  
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CHAPTER V: DISCUSSION 
 
P/pro ratio  
Patients consuming favorable P/pro ratios had lower serum K, lower dietary P intakes, 
higher dietary pro intakes, improved KDQOL physical composite scores, reduced levels of 
hsCRP, higher DPI, and improved serum total cholesterol.  This group also showed trends 
towards improved measures of muscle mass and muscle strength.  Noori, et. al, analyzed 
P/pro intakes using food frequency questionnaires (FFQs) and found that both higher 
dietary P intake and higher dietary P/pro ratios were each associated with increased death 
risk in MHD patients; however, associations between P/pro ratio on biochemical and 
anthropometric parameters were not addressed.(1) 
 
A greater proportion of Chinese patients consumed favorable P/pro ratios, followed by 
Malay patients, whereas Indian patient’s intake was of a predominantly unfavorable P/pro 
pattern.  Favorable P/pro intakes appear to be influenced more by traditional dietary intake 
patterns rather than adherence to renal nutrition guidelines.  Further exploration into the 
types of foods chosen, methods of preparation, and meal and snack patterns may reveal the 
underlying cause for this favorable intake of P/pro. 
 
Measurements of muscle mass 
One of the four main categories recognized in the diagnosis of PEW is muscle mass, as 
measured by MAMA or creatinine appearance per ISRNM guidelines.  Although reduction 
in muscle mass is the most valid criterion for PEW diagnosis(11), the best method for taking 
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this measurement has been debated.(105)  Accurate assessment of MAMC and MAMA 
requires training in anthropometry, yet it has been found that renal dietitians either lack the 
skills to execute these measurements or fail to take body composition measurements.(106; 
107)  In this study, results from both the BIA for lean and fat tissue masses and HGS, a 
surrogate marker of muscle strength, were positively correlated with MAMA, with BIA 
providing the strongest correlation.  Similarly, Isoyama, et. al. found positive associations 
between HGS and muscle mass in a study of MHD patients with a mean age of 53.(32)  The 
mean HGS in kg for both men and women was 21.7 and 15.1, respectively.  Normative 
HGS for a 55-year-old right-handed male is 45.9 and 26.0 for a female,(108) approximately 
twice the strength than that found in this HD population.   Currently, no standardized HGS 
tables for the HD population exists.  Given the ease and minimal training required to 
complete BIA analysis and HGS test, consideration for use of these testing methods for the 
HD population has been proposed as a complementary measurement to MAC and TSF for 
determination of muscle mass.(35; 109)   
 
In relation to the effects of exercise on body composition, the group of patients who 
reported exercising had lower fat mass and BMI, and slightly higher HDL, serum albumin 
and hsCRP; however, exercise did not improve their measures of muscle mass (lean tissue 
mass and HGS).  Our findings contrast reports that exercise, particularly resistance training, 
improves muscle mass in HD patients; however, most published studies examining the 
anabolic effect of exercise on muscle mass involve a younger HD population.(110; 111)  Given 
the median age of our study group was 55 years, sarcopenia related muscle wasting may 
have offset the anabolic benefits derived from exercise.  
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PEW 
Fouque, et, al. reported that 18–75% of ESRD patients exhibit evidence of PEW;(11)  we 
found a similar PEW prevalence of 15%, with 22% of the patient population presenting 
two PEW criteria and 48% with at least one diagnostic criteria. 
 
No difference was found in the overall caloric intake between the favorable and 
unfavorable P/pro groups.  Both groups had an average consumption of less than 25 kcals 
per kg.  Per the IRSM guidelines for diagnosing PEW, an unintentional low dietary energy 
intake of < 25 kcal/kg/day is one of the criteria in diagnosing PEW.   Lower DEI and DPI 
found in this Malaysian population produced slightly higher DEI for both genders and 
lower DPI for men than that found in the HEMO study (DEI and DPI for men and women 
in the HEMO study: 23.8 ± 8.4 and 21.7 ± 8.1, 0.97 ± 3.6 and 0.90 ± 3.4, respectively)(40)  
In this study, an analysis was also completed using DPI in lieu of DEI in identifying PEW 
patients; however, results did not produce significant differences. 
 
Limitations of the Study  
 
This study has several limitations.  Estimation of total P intake was used in this analysis 
since current nutrient databases do not distinguish between sources of inorganic and 
organic P.  The sample size was small, and a larger size may have been necessary to 
produce statistically significant results between favorable P/pro intakes and PEW 
parameters.  Given patients typically underreport foods eaten, the values derived from 
dietary recalls may have underestimated nutrient intakes, impacting identification of 
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patients with PEW indices.  Only one biomarker of inflammation (hsCRP) was measured; 
additional inflammatory markers, such as ferritin, interleukin 6 (Il-6) and tumor necrosis 
factor alpha (TNF-α) may have revealed stronger associations between P/pro ratio and 
PEW parameters or have provided a biomarker in patients identified in exhibiting PEW 
characteristics.   
 
 
Conclusions and Recommendations 
 
A mixed diet contains approximately 12–14 mg of P per gram of pro.  Based on an upper 
limit of 12 mg/g P/pro used to distinguish foods with a favorable ratio, a P pyramid has 
been proposed by D’Alessandro, et. al. as a tool in dietary P management for CKD 
patients.(82)  By analyzing differences between favorable (< 12 mg/g P/pro) and unfavorable 
(> 12 mg/g P/pro) intakes within this Malaysian HD study group in relation to various 
biochemical and body composition parameters, it was found that favorable P/pro intakes 
are inversely associated with PEW parameters of muscle mass and DPI.  Both Chinese 
ethnicity and exercise habits appear to drive favorable P/pro intakes.  A secondary outcome 
from this study includes findings that, when compared to measurements of MAMA, both 
BIA analysis and HGS are both valuable markers for lean body mass.  A larger data set of 
HGS for the HD population would provide a valuable standard reference for the 
identification of reduced muscle mass, which may be considered when diagnosing PEW. 
 
Recommendation for future studies include data collection from a different ethnic group, 
such as an African American population from the United States, to analyze differences in 
both clinical care, PEW parameters, P/pro ratio, and the ethnic influences on food intake 
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patterns.  Additionally, a larger data set of HGS for the HD population would contribute to 
standardized tables for the identification of reduced muscle mass, which may be considered 
when diagnosing PEW.   
 
In the Malaysian clinics, there was no restriction on eating during the HD session, a practice 
which may allow for improved nutritional status.    In contrast, US clinics follow stricter 
guidelines in allowing patients to eat while on HD.(112)  Patient education practices differ 
between countries as well.  The patient load per dietitian in the Malaysian non-
governmental organization (NGO) clinics was approximately 1 to 500, as opposed to the 
median average in the United States of 1 to 150.(43)  Examining the differences between 
counseling approaches, education provided, patient behaviors, PEW parameters, and P/pro 
ratio remains largely unexplored.   
Educating HD patients about P containing food additives has been shown to reduced serum 
P levels.(113)  Examination of several written renal diet educational materials from both the 
Academy of Nutrition and Dietetics’ Nutrition Care Manual and the National Institute of 
Health’s National Kidney Disease Education Program (NKDEP) reveal that phosphorus 
additives are addressed; however, information on the bioavailability of legumes, nuts, 
seeds, and chocolate is not included, as these foods are listed only as high in P.  
Additionally, neither the aforementioned materials, nor the phosphorus food pyramid 
provides information on yeast leavened breads as a lower P choice over quick breads 
leavened with baking powder.   Gaps in nutrition education provided to HD patients related 
to P/pro ratio and P bioavailability, coupled with a potentially over restrictive diet and high 
pill burden that may lead to poor diet/binder adherence, diminished intakes of protein and 
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lower intakes of antioxidant rich foods – factors implicated in hyperphosphatemia, PEW, 
and increased all cause and cardiovascular mortality -- warrant further exploration with a 
larger sample size.  Should this larger sample demonstrate that favorable P/pro intakes are 
associated with improved parameters of PEW, education with emphasis in choosing foods 
based on the ratio of P/pro, rather than limiting foods based on P content alone, may be 
warranted. 
Furthermore, identification and validation of prognostic nutritionally related biomarkers 
such as FGF-23, Fetuin A, and interleukin 6 (IL-6), remains an area of research that 
requires full scale testing.(114)  Additionally, potential use of an “omics” approach is 
emerging as a promising method to identify new biomarkers in the pathogenesis of PEW 
and phosphate control.(115) 
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Both higher dietary phosphorus intake and a greater dietary phosphorus to protein ratio are 
associated with increased death risk in hemodialysis (HD) patients even after adjustments 
for serum phosphorus, type of phosphate binder used, and dietary protein, energy, and 
potassium intake. Furthermore, dietary phosphorus restriction to control serum phosphorus 
is often associated with a reduction in protein intake, which is associated with muscle 
wasting and poor survival.  One highly prevalent complication of end stage renal disease 
is protein energy wasting (PEW), a state of decreased body protein and fat mass, which is 
strongly associated with increased morbidity and mortality in the HD population.   
 
In a cross sectional study of 60 Malaysian HD patients, the extent to which diet composition 
associated with PEW parameters (serum chemistry, body mass, muscle mass, and dietary 
intakes), was analyzed. 
 
It was found that favorable phosphorus to protein (P/pro) intake was inversely associated 
with PEW parameters of muscle mass and dietary protein intake.  Both Chinese ethnicity 
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and exercise habits appear to drive favorable P/pro intakes.  A secondary outcome from 
this study included findings that, when compared to measurements of mid-arm muscle area, 
both bio impedance analysis and hand grip strength were both valuable markers for lean 
body mass. 
 
